Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: A retrospective study

Journal of Thoracic Oncology

Volumn 7, Issue 3, 2012, Pages 528-534

  Lee, Gyeong Won ^a,b   Go, Se IL ^a,b   Cho, Yu Ji ^a,b,c   Jeong, Yi Yeong ^a,b,c   Kim, Ho Cheol ^a,b,c   Duk Lee, Jong ^a,b,c   Hwang, Young Sil ^a,b,c   Ko, Gyung Hyuck ^a,b   Lee, Jeong Hee ^a,b   Kim, Dong Chool ^a,b   Yang, Jung Wook ^a,b   Oh, Sukjoong ^d   Lee, Jong Sil ^a,b  

^a Gyeongsang National University School of Medicine   (South Korea)

^b Gyeongnam Regional Cardiocerebrovascular Disease Center   (South Korea)

^c Gyeongsang National University   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

ERCC1; HIF 1 ; Platinum; Small cell lung cancer; Survival

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRINOTECAN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; UNIVERSITY HOSPITAL;

EID: 84862776660     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182417830     Document Type: Article

References (36)

1. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366: 1385-1396. (Pubitemid 41443406)
2. Sandler AB. Chemotherapy for small cell lung cancer. Semin Oncol 2003;30:9-25. (Pubitemid 36254671)
3. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-392. (Pubitemid 38101633)
4. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66. (Pubitemid 46148091)
5. Shin HR, Jung KW, Won YJ, et al. 2002 annual report of the Korea Central Cancer Registry: based on registered data from 139 hospitals. Cancer Res Treat 2004;36:103-114.
6. Lee HW, Han JH, Kim JH, et al. Expression of excision repair crosscomplementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer 2008;59:95-104.
7. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-4544. (Pubitemid 46630948)
8. Kwon HC, Roh MS, Oh SY, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/ oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007;18:504-509. (Pubitemid 46359630)
9. Kawashima A, Nakayama M, Kakuta Y, et al. Excision repair crosscomplementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer. Clin Cancer Res 2011;17: 2561-2569.
10. Scheil-Bertram S, Tylus-Schaaf P, du Bois A, et al. Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma. Gynecol Oncol 2010;119:325-331.
11. Kim SH, Kwon HC, Oh SY, et al. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol 2009;32:38-43.
12. Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007;18:522-528. (Pubitemid 46359633)
13. Joshi MB, Shirota Y, Danenberg KD, et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005; 11:2215-2221.
14. Kim MK, Cho KJ, Kwon GY, et al. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer 2008;44:54-60. (Pubitemid 350256935)
15. Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005;127:978-983. (Pubitemid 40775532)
16. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007;25:2747-2754. (Pubitemid 47123183)
17. Ceppi P, Longo M, Volante M, et al. Excision repair cross complementing-1 and topoisomerase II alpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study. J Thorac Oncol 2008;3:583-589. (Pubitemid 351787300)
18. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010;16:5928-5935.
19. Wan J, Ma J, Mei J, et al. The effects of HIF-1alpha on gene expression profiles of NCI-H446 human small cell lung cancer cells. J Exp Clin Cancer Res 2009;28:150.
20. Hung JJ, Yang MH, Hsu HS, et al. Prognostic significance of hypoxiainducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax 2009;64:1082-1089.
21. Ioannou M, Papamichali R, Kouvaras E, et al. Hypoxia inducible factor-1 alpha and vascular endothelial growth factor in biopsies of small cell lung carcinoma. Lung 2009;187:321-329.
22. Nakamura J, Kitajima Y, Kai K, et al. HIF-1alpha is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy. Int J Cancer 2010; 127:1158-1171.
23. Kim MK, Kim TJ, Sung CO, et al. Clinical significance of HIF-2alpha immunostaining area in radioresistant cervical cancer. J Gynecol Oncol 2011;22:44-48.
24. Nam SY, Ko YS, Jung J, et al. A hypoxia-dependent upregulation of hypoxia-inducible factor-1 by nuclear factor-κβ promotes gastric tumour growth and angiogenesis. Br J Cancer 2011;104:166-174.
25. Kwon HC, Kim SH, Oh SY, et al. Clinicopathological significance of p53, hypoxia-inducible factor 1alpha, and vascular endothelial growth factor expression in colorectal cancer. Anticancer Res 2010;30:4163-4168.
26. Evens AM, Sehn LH, Farinha P, et al. Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2010;28: 1017-1024.
27. Han JY, Oh SH, Morgillo F, et al. Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 2005;97:1272-1286. (Pubitemid 41535368)
28. Moser C, Lang SA, Mori A, et al. ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma (HCC) cells, and inhibits growth and vascularization in vivo. BMC Cancer 2008;8:206.
29. Kummar S, Raffeld M, Juwara L, et al. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1{alpha} (HIF-1{alpha}) in advanced solid tumors. Clin Cancer Res 2011;17:5123-5131.
30. Tanno S, Ohsaki Y, Nakanishi K, et al. Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer 2004;46:11-19. (Pubitemid 39201379)
31. Fontanini G, Faviana P, Lucchi M, et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 2002;86:558-563. (Pubitemid 34185092)
32. Kim SJ, Rabbani ZN, Dewhirst MW, et al. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 2005;49:325-335. (Pubitemid 41139145)
33. Lau SK, Boutros PC, Pintilie M, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 2007;25:5562-5569.
34. Park S, Ha SY, Cho HY, et al. Prognostic implications of hypoxiainducible factor-1alpha in epidermal growth factor receptor-negative non-small cell lung cancer. Lung Cancer 2011;72:100-107.
35. Gitlitz BJ, Moon J, Glisson BS, et al. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol 2010;5: 1835-1840.
36. Knez L, Sodja E, Kern I, et al. Predictive value of multidrug resistance proteins, topoisomerases II and ERCC1 in small cell lung cancer: a systematic review. Lung Cancer 2011;72:271-279.